The C4C Consortium Announces the Implementation of France's First Ever Facility for the Industrialization of Cell Therapeutics and Presents the Five Drugs Under Development for Use in Personalized Medicine
10/22/2012 9:24:08 AM
PARIS--(BUSINESS WIRE)--The C4C consortium today announced the implementation of France's first ever dedicated technical facility for the manufacture of cell therapy products. The C4C project (coordinated by CELLforCURE, a subsidiary of the leading French biopharmaceutical company LFB Biotechnologies) brings together the skills of two biotech companies (Celogos and CleanCells) and seven public-sector organizations and university medical centers (the French Blood Agency's [Etablissement Français du Sang, EFS] directorates in the Aquitaine-Limousin and Pyrénées-Méditerranée regions of France, Bordeaux University Medical Center [CHU de Bordeaux], Lille University Medical Center/University of Lille 2 [CHU de Lille], Nantes University Medical Center, [CHU de Nantes] and the Biological Resource Center at Lyons University Medical Center [Banque de Tissus et de Cellules des Hospices Civils de Lyon]. The first five products are currently being developed, with a view to validating the facility dedicated to the routine production of clinical trial and therapeutic batches. This facility is located on LFB's site in Les Ulis, close to Paris.
comments powered by